Organization: Franc-Or Corp

URRMA shareholders invest additional $2 million

Shareholders in URRMA Biopharma have exercised their options for an additional investment of $2 million in the Montreal-based developer of products to diagnose and treat HIV infection. Franc-Or Corp invested $1 million while Innovatech Grand Montréal and Dacha Capital invested $500,000 each. Franc-Or now holds a 26% interest in URRMA. The new funding is for…